Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
palazestrant + everolimus
- Development stage
- Unknown
- Lead developer
- Olema Oncology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of palazestrant (OP-1250), a novel oral complete estrogen receptor (ER) antagonist, and everolimus, an mTOR inhibitor. This combination is being investigated for the treatment of advanced and/or metastatic ER-positive, HER2-negative breast cancer. The combination aims to simultaneously target the estrogen receptor pathway and the mTOR signaling pathway to potentially overcome resistance mechanisms in ER-positive breast cancer.
- Other names
- Palazestrant + everolimus
02
Targets
Mechanistic target of rapamycin complex 1ESR1 (ERα)
Beyond the preview
Go deeper on palazestrant + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on palazestrant + everolimus.